This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

In Global News: Expanded MitraClip Indications, Congenital Heart Surgery After Fukushima Accident, and Reducing Blood Utilization in Cardiac Surgery

Friday, March 15, 2019

Submitted by



Claire Vernon

Drugs and Devices

The US Food and Drug Administration (FDA) announced that the indications for the MitraClip™, made by Abbott, have been expanded to include secondary mitral regurgitation.

Saranas, Inc, announced that it’s Early Bird Bleed Monitoring System for detecting bleeding events during endovascular procedures was granted de novo classification by the US FDA.

European regulators offered decisions on immunotherapies for treating advanced lung cancer, with Roche’s atezolizumab and Merck’s pembrolizumab receiving approvals for expanded indications from the European Commission, and Pfizer’s lorlatinib being endorsed by the European Medicines Agency’s drug review panel.


Research, Trials, and Funding

An educational initiative that provided cardiac surgeons with information on their transfusion rates reduced blood utilization without affecting quality measures, a finding that was presented at the recent American College of Cardiology’s Cardiovascular Summit in Orlando, Florida.

Researchers in Japan report that the number of operations performed for complex congenital heart disease in Japan increased following the 2011 earthquake and nuclear accident in Fukushima.

Cardiac MRI shows promise for predicting allograft rejection in heart transplant recipients, say researchers from Chicago, Illinois, USA.

Add comment

Log in or register to post comments